2019 Biomanufacturing World Summit in La Jolla, California – November 11-12

Compliance Architects® is proud to be a sponsor and participant of the 2019 Biomanufacturing World Summit presented by our friends at Executive Platforms. Taking place in beautiful La Jolla, California, and heralded as, "The Must-Attend Event for Biopharmaceutical Executives," BMWS brings together the “who’s who” of pharmaceutical executives, cutting-edge technology pr... Read more

Medical Device Innovation Consortium Case for Quality Forum – November 6th in Wahsington, D.C.

On November 6th, CEO Jack Garvey will be attending the MDIC Case for Quality Forum in Washington, D.C. The Forum will focus the Case for Quality Voluntary Improvement Program (CFQ VIP) and plans to grow the program in 2020 and beyond. Topics include: A keynote presentation on Collaborations in Digital Health and new initiatives at CDRH A panel discussion on the future on the Case... Read more

CDRH Proposed Guidances for Fiscal Year 2020 (FY 2020)

from FDA The lists on this page include guidance documents that CDRH intends to publish this fiscal year (FY 2020), as well as previously-issued final guidances for which CDRH is interested in receiving external feedback regarding whether these final guidances should be revised or withdrawn. These lists are: The A-list: A list of prioritized device guidance document... Read more

2020 American Medical Device Summit October 28-29 in Chicago, IL

Compliance Architects® is proud to be a sponsor of this year's American Medical Device Summit in Chicago, Illinois. Setting the standard on how the industry should connect and exchange ideas, the American Medical Device Summit provides insights and strategies to enhance the professional development of executives involved in the design, product development, innovation, technol... Read more

CEO Jack Garvey to Co-Host FDLI Webinar “Due Diligence: Ensuring Your Deal Doesn’t Collapse Due to Regulatory, Clinical, Quality, or Data Integrity Issues”

With the increasing difficulties in internally-generated product development, drug, biologics, and device firms of all sizes are looking to acquisitions to augment product lines. Whether in the form of single products or whole companies, transactions can make or break the future of a company. However, often lost in the frenzy of a deal involving highly-regulated biomedical companies or p... Read more